ISTA ANNOUNCES POSITIVE RESULTS FOR TOBRAMYCIN AND PREDNISOLONE ACETATE COMBINATION PRODUCT
Ista Pharmaceuticals has announced positive results from a Phase III bioequivalence study of the company's proprietary investigational combination ophthalmic product containing tobramycin and prednisolone acetate for the treatment of steroid-responsive inflammatory ocular conditions where risk of bacterial infection exists.
The multicenter, randomized, double-masked trial successfully achieved its primary endpoint, demonstrating bioequivalence of prednisolone between the company's combination product (tobramycin 0.3 percent/prednisolone acetate 1 percent) and prednisolone acetate 1 percent. To demonstrate that the two products were bioequivalent, the ratio of the concentrations of prednisolone needed to establish bioequivalence must fall between 80 percent and 125 percent, with 90 percent confidence.
Upcoming Events
-
25Apr
-
07May
-
14May
-
30May